Journal of Food and Nutrition Research
ISSN (Print): 2333-1119 ISSN (Online): 2333-1240 Website: http://www.sciepub.com/journal/jfnr Editor-in-chief: Prabhat Kumar Mandal
Open Access
Journal Browser
Go
Journal of Food and Nutrition Research. 2018, 6(11), 710-718
DOI: 10.12691/jfnr-6-11-6
Open AccessMeta-Analysis

Meta-Analysis Study the Role of Probiotics Treatment in Irritable Bowel Syndrome (1990-2017)

Selvaganapathi G.1, Jinat Ahmed J.A.2, , Mathialagan AG2, Dinesh M.3, Azra N.2, Harikrishnan T.4, Kohila J.R.1, Fathy I.5, Ramalinggam R.1, Tee HY2 and Vanita S.6

1Seremban Prison, Malaysian Prison Department, Home Ministry, Malaysia

2Department of Post-Graduate Studies, Perdana University, Malaysia

3SP Care Group, Health Care, Malaysia

4Department of Rehabilitation Medicine, Hospital Tunku Ampuan Rahimah, Ministry of Health, Malaysia

5Child Health Department, Sabak Bernam District Health Department, Ministry of Health, Malaysia

6Klinik Sri Pulai Sdn Bhd

Pub. Date: December 14, 2018

Cite this paper:
Selvaganapathi G., Jinat Ahmed J.A., Mathialagan AG, Dinesh M., Azra N., Harikrishnan T., Kohila J.R., Fathy I., Ramalinggam R., Tee HY and Vanita S.. Meta-Analysis Study the Role of Probiotics Treatment in Irritable Bowel Syndrome (1990-2017). Journal of Food and Nutrition Research. 2018; 6(11):710-718. doi: 10.12691/jfnr-6-11-6

Abstract

Objective: To examine the relationship between Probiotics and its efficacy in reducing the symptoms of Irritable Bowel Syndrome (IBS). Methods: A meta-analysis was conducted to evaluate the quality of the clinical trials and evidence with respect to the efficacy of probiotics for the treatment of IBS. Medline, PubMed, Google Scholar, NIH registry of clinical trials, and Cochrane Central Register of Controlled Trials were reviewed from the year 1990-2017 to identify studies that fulfilled inclusion criteria and exclusion criteria. Findings: 1650 studies were found on probiotics use in IBS. From that, only 70 studies fulfilled inclusion and exclusion criteria that were defined for this study. After assessment with Linde Internal Validity Scale, around 18 clinical trials were identified for data extraction. From those studies, it was seen that probiotic use was associated with improvement in global IBS symptoms compared to placebo [pooled relative risk (RRpooled) 0.77, 95% confidence interval (95% CI) 0.62-0.94]. Probiotics were also associated with less abdominal pain compared to placebo [RRpooled = 0.78 (0.69-0.88)]. Of the 11 species and species mixtures, Lactobacillus rhamnosus GG was the most frequent tested probiotics. None of the 18 trials reported any serious adverse events with probiotic use. Conclusion: For management of IBS, probiotics were significantly more protective and effective than placebo.

Keywords:
irritable bowel syndrome probiotics placebo-controlled randomized controlled trials Manning criteria Rome criteria double blinding

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Definition & Facts for Irritable Bowel Syndrome|NIDDK [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases. [Cited 2018 Nov 15]. Available from: https://www.niddk.nih.gov/health-information/digestive-diseases/irritable-bowel-syndrome/definition-facts
 
[2]  Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol. 2014 Feb 4; 6: 71-80.
 
[3]  Spiller R, Aziz Q, Creed F, Emmanuel A, Houghton L, Hungin P, et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut. 2007 Dec 1; 56(12): 1770-98.
 
[4]  Irritable bowel syndrome: treatment and management-ProQuest [Internet]. [Cited 2018 Nov 15].
 
[5]  Bausserman M, Michail S. The Use of Lactobacillus GG in Irritable Bowel Syndrome in Children: A Double-blind Randomized Control Trial. The Journal of Pediatrics. 2005 Aug; 147(2): 197-201.
 
[6]  Quigley e. m. m., flourie b. Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date. Neurogastroenterology & Motility. 2007 Mar; 19(3): 166-72.
 
[7]  McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol. 2008 May 7; 14(17): 2650-61.
 
[8]  Tuohy KM, Probert HM, Smejkal CW, Gibson GR. Using probiotics and prebiotics to improve gut health. Drug Discovery Today. 2003 Aug; 8(15): 692-700.
 
[9]  Kim HJ, Camilleri M, Mckinzie S, Lempke MB, Burton DD, Thomforde GM, et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Alimentary Pharmacology and Therapeutics. 2003 Apr; 17(7): 895-904.
 
[10]  Kajander K, Hatakka K, Poussa T, Färkkilä M, Korpela R. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Alimentary Pharmacology & Therapeutics. 2005 Sep 1; 22(5): 387-94.
 
[11]  Forest plot. In: Wikipedia [Internet]. 2018 [cited 2018 Nov 15]. Available from: https://en.wikipedia.org/w/index.php?title=Forest_plot&oldid=858290044.
 
[12]  Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O’Mahony L, et al. Efficacy of an Encapsulated Probiotic Bifidobacterium infantis 35624 in Women with Irritable Bowel Syndrome. The American Journal of Gastroenterology. 2006 Jul; 101(7): 1581-90.
 
[13]  Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. British Journal of Surgery. 2000 Nov; 87(11): 1448-54.
 
[14]  Kim h. j., vazquez roque m. i., camilleri m., stephens d., burton d. d., baxter k., et al. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterology and Motility. 2005 Oct; 17(5): 687-96.
 
[15]  O’Sullivan M. Bacterial supplementation in the irritable bowel syndrome. A randomised doubleblind placebo-controlled crossover study. Digestive and Liver Disease. 2000 May; 32(4): 294-301.
 
[16]  Maupas JL, Champemont P, Delforge M. Treatment of irritable bowel syndrome double blind trial of saccharomyces boulardii: 5.
 
[17]  Yoon JS, Sohn W, Lee OY, Lee SP, Lee KN, Jun DW, et al. Effect of multispecies probiotics on irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial: Probiotics in irritable bowel syndrome. Journal of Gastroenterology and Hepatology. 2014 Jan; 29(1): 52-9.
 
[18]  Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study-WILLIAMS-2009-Alimentary Pharmacology & amp; Therapeutics-Wiley Online Library [Internet]. [Cited 2018 Nov 15].
 
[19]  Simrén M, Öhman L, Olsson J, Svensson U, Ohlson K, Posserud I, et al. Clinical trial: the effect of a fermented milk containing three probiotic bacteria in patients with irritable bowel syndrome (IBS)-a randomized, double-blind, controlled study. Alimentary Pharmacology & Therapeutics [Internet]. 2009.
 
[20]  Nobaek S. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. The American Journal of Gastroenterology. 2000 May; 95(5): 1231-8.
 
[21]  EBSCOhost|16071930|Treatment of Irritable Bowel Syndrome with Lacteol Fort: A Randomized, Double-Blind, Cross-Over Trial. [Internet]. [Cited 2018 Nov 15].
 
[22]  Niedzielin K, Kordecki H, Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome: European Journal of Gastroenterology & Hepatology. 2001 Oct; 13(10): 1143-7.
 
[23]  Bittner AC, Croffut RM, Stranahan MC. Prescript-assistTM probiotic-prebiotic treatment for irritable bowel syndrome: A methodologically oriented, 2-week, randomized, placebo-controlled, double-blind clinical study. Clinical Therapeutics. 2005 Jun; 27(6): 755-61.
 
[24]  Spiller R, Pélerin F, Cayzeele Decherf A, Maudet C, Housez B, Cazaubiel M, et al. Randomized double blind placebo-controlled trial of Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: improvement in abdominal pain and bloating in those with predominant constipation. United European Gastroenterology Journal. 2016 Jun; 4(3): 353-62.
 
[25]  Niv E, Naftali T, Hallak R, Vaisman N. The efficacy of ATCC 55730 in the treatment of patients with irritable bowel syndrome-a double blind, placebo-controlled, randomized study. Clinical Nutrition. 2005 Dec; 24(6): 925-31.
 
[26]  Evans M, Salewski RP, Christman MC, Girard S-A, Tompkins TA. Effectiveness of Lactobacillus helveticus and Lactobacillus rhamnosus for the management of antibiotic-associated diarrhoea in healthy adults: a randomised, double-blind, placebo-controlled trial. British Journal of Nutrition. 2016 Jul; 116(01): 94-103.
 
[27]  Canani RB, Cirillo P, Terrin G, Cesarano L, Spagnuolo MI, Vincenzo AD, et al. Probiotics for treatment of acute diarrhoea in children: randomised clinical trial of five different preparations. BMJ. 2007 Aug 16; 335(7615): 340.
 
[28]  Wilhelm SM, Brubaker CM, Varcak EA, Kale-Pradhan PB. Effectiveness of Probiotics in the Treatment of Irritable Bowel Syndrome. Pharmacotherapy. 2008 Apr; 28(4): 496-505.
 
[29]  Lorenzo-Zúñiga V, Llop E, Suárez C, Álvarez B, Abreu L, Espadaler J, et al. I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life. World J Gastroenterol. 2014 Jul 14; 20(26): 8709-16.
 
[30]  Ducrotté P, Sawant P, Jayanthi V. Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroenterol. 2012 Aug 14; 18(30): 4012-8.
 
[31]  Barrett JS, Canale KE, Gearry RB, Irving PM, Gibson PR. Probiotic effects on intestinal fermentation patterns in patients with irritable bowel syndrome. World J Gastroenterol. 2008 Aug 28; 14(32): 5020-4.
 
[32]  Cimperman L, Bayless G, Best K, Diligente A, Mordarski B, Oster M, et al. A Randomized, Double-blind, Placebo-controlled Pilot Study of Lactobacillus reuteri ATCC 55730 for the Prevention of Antibiotic-associated Diarrhea in Hospitalized Adults. Journal of Clinical Gastroenterology. 2011 Oct; 45(9): 785.
 
[33]  Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D. St John’s wort for depression-an overview and meta-analysis of randomised clinical trials. BMJ. 1996 Aug 3; 313(7052): 253-8.
 
[34]  Linde K, Clausius N, Ramirez G, Melchart D, Eitel F, Hedges LV, et al. Are the clinical effects of homoeopathy placebo effects? A meta-analysis of placebo-controlled trials. The Lancet. 1997 Sep; 350(9081): 834-43.